To study the effect of Atorvastatin on thyroid eye disease
Phase 2
- Conditions
- Health Condition 1: E050- Thyrotoxicosis with diffuse goiter
- Registration Number
- CTRI/2024/07/070367
- Lead Sponsor
- Armed Forces Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Confirmed diagnosis of graves disease
2. Willingness to give consent
Exclusion Criteria
1. Previous treatment with statins within the past 6 months.
2. Contraindications to statin therapy.
3. History of other diseases affecting the thyroid or orbit.
4. Pregnancy or lactation.
5. Patients who did not provide informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Improvement in clinical activity scoreTimepoint: 6 months post initiation of statin therapy
- Secondary Outcome Measures
Name Time Method 2.Changes in CBC, LFTs, and RFTs from baseline, particularly focusing on any adverse effects related to statin therapy.Timepoint: 6 months post initiation of statin therapy